Cramer: Apple Is Th...
Health Care: Drugs
AEterna Zentaris Inc. (AEZS: NASDAQ)
$0.47 -0.01 | -2.10%
06/01/12 - 03:59 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 46.88M | 32.00M | 38.10M | 49.23M |
| Receivables | 8.32M | 4.67M | 3.44M | 4.52M |
| Inventories | 3.46M | 3.31M | 4.42M | 3.38M |
| Other Current Assets | 0.00 | 748.00K | 113.00K | 48.00K |
| Total Current Assets | 60.14M | 44.18M | 49.01M | 61.72M |
| Property, Plant & Equipment, Gross | 11.04M | 13.38M | 14.68M | 12.99M |
| Accumulated Depreciation & Depletion | 8.52M | 10.29M | 10.32M | 6.31M |
| Property, Plant & Equipment, Net | 2.51M | 3.10M | 4.36M | 6.68M |
| Intangibles | 1.77M | 14.48M | 17.03M | 23.89M |
| Other Non-Current Assets | 1.64M | 5.21M | 5.61M | 5.96M |
| Total Non-Current Assets | 15.23M | 32.40M | 37.25M | 46.62M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 75.37M | 76.57M | 86.26M | 108.34M |
| Accounts Payable | 8.12M | 9.44M | 8.15M | 10.26M |
| Short Term Debt | 42.00K | 0.00 | 0.00 | 49.00K |
| Other Current Liabilities | 1.24M | 0.00 | 1.02M | 1.70M |
| Total Current Liabilities | 17.88M | 13.49M | 19.27M | 22.17M |
| Long Term Debt | 29.00K | 0.00 | 0.00 | 172.00K |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 62.00M | 50.65M | 57.77M | 64.52M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 62.03M | 50.65M | 57.77M | 64.70M |
| Total Liabilities | 79.92M | 64.14M | 77.04M | 86.87M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -4.55M | 12.44M | 9.23M | 21.48M |
| Common Par | 82.33M | 140.93M | 79.94M | 0.00 |
| Additional Paid In Capital | 101.88M | 0.00 | 41.20M | 110.24M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 14.05M |
| Retained Earnings | -188.97M | -150.76M | -127.54M | -102.81M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 212.00K | 22.26M | 15.62M | 3.00K |
| Total Capitalization | -4.52M | 12.44M | 9.23M | 21.65M |
| Total Equity | -4.55M | 12.44M | 9.23M | 21.48M |
| Total Liabilities & Stock Equity | 75.37M | 76.57M | 86.26M | 108.34M |
| Total Common Shares Outstanding | 104.76M | 83.43M | 63.09M | 53.19M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 94.51M | 75.66M | 56.86M | 53.19M |
| Diluted Weighted Shares Outstanding | 94.51M | 75.66M | 57.18M | 53.19M |
| Number of Employees | 89 | 88 | 99 | 109 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with AEZS
- Portfolio NameUser Type
- UserMillion Dollar Portfolio
- Userwright stocks
- UserSMITTY
- UserFiuza 1
- Userherb's portfolio
- Contributor10 Pharma Stocks Under $3
- UserMy Portfolio
- Contributor4 Biotech Penny Stocks to Buy
- Contributor10 Cheap Stocks to Buy for ...
- UserBunny Money
Latest AEZS Headlines from TheStreet
- ASCO '12: Colon Cancer Drugs Good (Roche) and Very Bad (Keryx Pharma) 06.03.12 | 06:06 am
- Keryx: Lessons From a Drug Failure 04.02.12 | 12:04 pm
- AEterna Zentaris Stock Gaps Down On Today's Open (AEZS) 04.02.12 | 09:04 am
- Keryx: Perifosine Colon Cancer Trial Fails 04.02.12 | 07:04 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- As Keryx, Aeterna Shares Surge, Investing Writer's Credibility Questioned 03.06.12 | 01:03 pm
- AEterna Zentaris Stock Gaps Down On Today's Open (AEZS) 03.06.12 | 08:03 am
- Keryx Rises With Hopes on Cancer Drug 03.06.12 | 05:03 am
- 10 Biotech Stock Predictions for 2012 12.20.11 | 11:12 am
- Biotech Stock Mailbag: Prostate Cancer Drug Reaction 11.04.11 | 05:11 am
Press Releases for AEZS
- Aeterna Zentaris: Article On Perifosine As Potential Novel Approach To The Treatment Of Mesothelioma Published In Plos One - PR Newswire 05.31.12 | 07:05 am
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In AEterna Zentaris Inc. To Contact The Firm - PR Newswire 05.25.12 | 07:05 pm
- Aeterna Zentaris Receives Notification From NASDAQ Relating To Minimum Bid Price - PR Newswire 05.16.12 | 04:05 pm
- Aeterna Zentaris Presents Preclinical Data For Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, At AACR Meeting - PR Newswire 04.03.12 | 07:04 am
- Aeterna Zentaris Announces Top-Line Data From The Perifosine Phase 3 Trial In Refractory Advanced Colorectal Cancer - PR Newswire 04.02.12 | 07:04 am
- Aeterna Zentaris To Present At Needham Healthcare Conference In New York - PR Newswire 03.29.12 | 07:03 am
- Aeterna Zentaris To Announce Fourth Quarter And Full Year 2011 Financial And Operating Results On March 27, 2012 - PR Newswire 03.20.12 | 07:03 am
- Michael E. DeBakey VA Medical Center Initiates Phase 2A Trial In Cancer Cachexia With Aeterna Zentaris' Ghrelin Agonist, AEZS-130 - PR Newswire 03.08.12 | 07:03 am
- Aeterna Zentaris To Present At Cowen And Company 32nd Annual Health Care Conference In Boston - PR Newswire 02.29.12 | 07:02 am
- Aeterna Zentaris To Present At BIO CEO Investor And RBC Capital Markets Global Healthcare Conferences In New York - PR Newswire 02.07.12 | 07:02 am
Partner Headlines for AEZS
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris - Seeking Alpha 03.02.12 | 05:03 pm
- 5 High-Risk, High-Reward Biopharma Stocks - Seeking Alpha 02.14.12 | 09:02 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 02.01.12 | 09:02 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 01.26.12 | 09:01 am
- 3 Biotechs Hopefully To Get Rich Or Die Trying - Seeking Alpha 01.04.12 | 08:01 am
- 7 Stocks Below $10 That Analysts Expect To Double - Seeking Alpha 12.05.11 | 08:12 am
- Biotechs And Their Trials By Fire - Seeking Alpha 11.07.11 | 09:11 am
- Keryx Biopharmaceuticals: Volatility Could Potentially Produce Monetary Gains - Seeking Alpha 10.23.11 | 09:10 am
